Artificial intelligence based advancements in nanomedicine for brain disorder management: an updated narrative review DOI Creative Commons
Pankaj Dipankar, Diego Salazar, Elizabeth Dennard

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: May 13, 2025

Nanomedicines are nanoscale, biocompatible materials that offer promising alternatives to conventional treatment options for brain disorders. The recent technological developments in artificial intelligence (AI), particularly machine learning (ML) and deep (DL), transforming the nanomedicine field by improving disease diagnosis, biomarker identification, prognostic assessment monitoring, targeted drug delivery, therapeutic intervention as well contributing computational methodological developments. These advancements can be achieved analysis of large clinical datasets facilitating design optimization nanomaterials vivo testing. Such advancement offers exciting possibilities improvement management disorders, including cancer, Alzheimer’s disease, Parkinson’s multiple sclerosis, where early effective strategies remain a great challenge. This review article provides an overview advances AI-based development accelerate quick prognosis, patient-specific therapies managing

Language: Английский

Artificial intelligence based advancements in nanomedicine for brain disorder management: an updated narrative review DOI Creative Commons
Pankaj Dipankar, Diego Salazar, Elizabeth Dennard

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: May 13, 2025

Nanomedicines are nanoscale, biocompatible materials that offer promising alternatives to conventional treatment options for brain disorders. The recent technological developments in artificial intelligence (AI), particularly machine learning (ML) and deep (DL), transforming the nanomedicine field by improving disease diagnosis, biomarker identification, prognostic assessment monitoring, targeted drug delivery, therapeutic intervention as well contributing computational methodological developments. These advancements can be achieved analysis of large clinical datasets facilitating design optimization nanomaterials vivo testing. Such advancement offers exciting possibilities improvement management disorders, including cancer, Alzheimer’s disease, Parkinson’s multiple sclerosis, where early effective strategies remain a great challenge. This review article provides an overview advances AI-based development accelerate quick prognosis, patient-specific therapies managing

Language: Английский

Citations

0